Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial.

被引：0
|
作者：
Meluch, AA
Spigel, DS
Greco, FA
Barton, JH
Messina, G
Gould, B
Rovito, MA
Hainsworth, JD
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Wellstar Hlth Syst Canc Res, Marietta, GA USA
[3] Consultants Med Oncol & Hematol, Drexel Hill, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：436S / 436S
页数：1
相关论文
共 50 条
  • [31] Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network
    Hainsworth, JD
    Burris, HA
    Erland, JB
    Baker, M
    Scullin, DC
    Shaffer, DW
    Greco, FA
    CANCER INVESTIGATION, 2003, 21 (02) : 193 - 199
  • [32] Weekly Docetaxel and Pegylated liposomal doxorubicin (PLD) in metastatic hormone refractory prostate cancer (HRPC)
    Pacilio, G.
    De Filippis, L.
    Simeon, D.
    De Domenico, R.
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 154
  • [33] Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium - A phase II trial of the Minnie Pearl Cancer Research Network
    Hainsworth, JD
    Meluch, AA
    Litchy, S
    Schnell, FM
    Bearden, JD
    Yost, K
    Greco, FA
    CANCER, 2005, 103 (11) : 2298 - 2303
  • [34] Phase II trial of weekly docetaxel and oral capecitabine in metastatic hormone-refractory prostate cancer.
    Marur, S.
    Heilbrun, L.
    Kucuk, O.
    Cher, M. L.
    Forman, J.
    Heath, E.
    Vaishampayan, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 250S - 250S
  • [35] A phase II trial of 13-cis retinoic acid, interferon, docetaxel, and estramustine (RITE) for the treatment of hormone refractory prostate cancer (HRPC)
    Mehta, A.
    Stein, M. N.
    Goodin, S.
    Doyle-Lindrud, S.
    Todd, M.
    Rubin, E.
    White, E.
    Jeyamohan, C.
    Metzger, D.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer
    Kolodziej, Michael
    Neubauer, Marcus A.
    Rousey, Steven R.
    Pluenneke, Robert E.
    Perrine, George
    Mull, Stephanie
    Boehm, Kristi A.
    Ilegbodu, Des
    Asmar, Lina
    CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 155 - 161
  • [37] High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial.
    Kasimis, B
    Cogswell, J
    Hwang, S
    Chang, VT
    Srinivas, S
    Zhong, F
    Duque, L
    Morales, E
    Boholli, I
    Blumenfrucht, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 428S - 428S
  • [38] Preoperative docetaxel and gemcitabine in resectable non-small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network
    Thompson, D. S.
    Spigel, D. R.
    Greco, F. A.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E.
    Erland, J.
    Shipley, D. L.
    Spremulli, E.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC)
    Dreicer, R.
    Garcia, J.
    Smith, S.
    Elson, P.
    Triozzi, P.
    Hodnick, S.
    Rini, B.
    Klein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial
    Hainsworth, JD
    Kalman, L
    Castine, M
    Sylvester, L
    Greco, FA
    GYNECOLOGIC ONCOLOGY, 2005, 97 (01) : 200 - 205
12345